DOCSLIB.ORG

ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy in Vitro

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy in Vitro Research Article ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy In vitro Dennis A. Eichenauer,1 Vijaya Lakshmi Simhadri,1 Elke Pogge von Strandmann,1 Andreas Ludwig,3 Vance Matthews,4 Katrin S. Reiners,1 Bastian von Tresckow,1,2 Paul Saftig,3 Stefan Rose-John,2 Andreas Engert,1 and Hinrich P. Hansen1 1Department of Internal Medicine I and 2Center for Molecular Medicine, University Hospital Cologne, Cologne, Germany; 3Department of Biochemistry, University of Kiel, Kiel, Germany; and 4Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Victoria, Melbourne, Australia Abstract Due to its selective expression, CD30 is generally well suited for CD30 is a transmembrane protein selectively overexpressed on targeted immunotherapy of CD30-positive lymphomas. Although many human lymphoma cells and therefore an interesting antibody-based reagents against CD30 showed impressive anti- target for antibody-based immunotherapy. However, binding tumor activity in experimental Hodgkin’s lymphoma models, early of therapeutic antibodies stimulates a juxtamembrane cleav- clinical trials suffered from dose-limiting toxicities (4). A problem age of CD30 leading to a loss of target antigen and an that appeared was the formation of complexes containing the enhanced release of the soluble ectodomain of CD30 (sCD30). therapeutic antibody and the soluble ectodomain of CD30 (sCD30). Here, we show that sCD30 binds to CD30 ligand (CD153)– sCD30 is generated by proteolytic cleavage of CD30 (5). The release expressing non-target cells. Because antibodies bind to sCD30, of extracellular domains, also referred to as ectodomain shedding, this results in unwanted antibody binding to these cells via is a general process regulating the function of membrane proteins sCD30 bridging. To overcome shedding-dependent damage of (6). In most cases, shedding is catalyzed by metalloproteinases. The normal cells in CD30-specific immunotherapy, we analyzed tumor necrosis factor-a (TNF-a)–converting enzyme, also known the mechanism involved in the release. Shedding of CD30 can as a disintegrin and metalloproteinase 17 (ADAM17), is the be enhanced by protein kinase C (PKC) activation, implicating metalloproteinase responsible for the ectodomain release of many the disintegrin metalloproteinase ADAM17 but not free membrane proteins, including CD30 (7, 8). A structurally related cytoplasmic calcium. However, antibody-induced CD30 shed- proteinase (ADAM10) is also implicated in certain shedding ding is calcium dependent and PKC independent. This processes, suchas thenon-amyloidogenic processing of Alz- shedding involved the related metalloproteinase ADAM10 as heimer’s amyloid precursor protein (APP; ref. 9) or the cleavage of shown by the use of the preferential ADAM10 inhibitor N-cadherin and E-cadherin (10, 11). GI254023X and by an ADAM10-deficient cell line generated Many studies distinguish between the mechanisms underlying À À from embryonically lethal ADAM10 / mouse. In coculture the constitutive shedding of unstimulated cells and the release from experiments, the antibody-induced transfer of sCD30 from stimulated cells. Classic shedding stimulation is initiated by the the human Hodgkin’s lymphoma cell line L540 to the CD30- protein kinase C (PKC) activator phorbol 12-myristate-13-acetate negative but CD153-expressing human mast cell line HMC-1 (PMA), and there is evidence for an implication of ADAM17 (12). In was inhibited by GI254023X. These findings suggest that some cases, including CD30, membrane protein shedding is also selective metalloproteinase inhibitors blocking antibody- stimulated by antibody binding (6, 13). As the release of soluble induced shedding of target antigens could be of therapeutic antigen from tumor cells has far-reaching implications for targeted value to increase the specificity and reduce side effects of immunotherapy, our group has investigated the use of metal- immunotherapy with monoclonal antibodies. [Cancer Res loproteinase inhibitors to block the release of the target antigen 2007;67(1):332–8] (14). In a mouse model, we showed that an anti-CD30 immunotoxin was only effective against human Hodgkin’s lymphoma tumors Introduction when concomitantly used with the broad-spectrum hydroxamic A common feature of Hodgkin’s lymphoma and large cell acid–based metalloproteinase inhibitor BB-3644 (15). Such nonse- anaplastic lymphoma is the strong surface expression of CD30, lective inhibitors block many different metalloproteinases, includ- a type I transmembrane receptor (1). Healthy donors express ing essential matrix and disintegrin metalloproteinases. They have CD30 exclusively on very few cells, predominantly on activated been used in clinical studies, and the broad specificity resulted in lymphocytes. In contrast, the cognate ligand (CD153), a membrane- more unspecific toxicity than antitumor effects (16). Thus, more anchored type II glycoprotein, is expressed on the cell surface of selective inhibitors are desirable for clinical use. many different cell types, including resting B cells, activated T cells, Here, we analyze the mechanism of antibody-stimulated release mast cells, monocytes, and granulocytes (2, 3). of sCD30. We found that antibody-induced CD30 shedding was not catalyzed by the previously described ADAM17 but instead by ADAM10. Moreover, we show that immunocompetitive sCD30 not only resided in a soluble form in the pericellular environment but Requests for reprints: HinrichHansen, Department of Internal Medicine I, also specifically bound to membrane-anchored CD30 ligand University Hospital Cologne, LFI, Ebene 4, Room 703, Kerpener Str. 62, 50924 Cologne, (CD153) on non-target cells where it generated novel targeting Germany. Phone: 49-221-478-5808; Fax: 49-221-478-3778; E-mail: [email protected]. I2007 American Association for Cancer Research. sites. Application of an ADAM10-selective metalloproteinase doi:10.1158/0008-5472.CAN-06-2470 inhibitor significantly reduced this mistargeting. Cancer Res 2007; 67: (1). January 1, 2007 332 www.aacrjournals.org Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 2007 American Association for Cancer Research. ADAM10 Inhibition and Specificity of CD30 Targeting Materials and Methods Construction and expression of CD153-glutathione S-transferase fusion + À protein. The ectodomain of CD153 was amplified by PCR using cDNA from Cells and reagents. We used the CD30 /CD153 cell lines L540 DG75 cells and the primers 5¶-CGACAGGATCCCCGTTCAGAGGACG- (Hodgkin’s lymphoma) and Karpas 299 (large cell anaplastic lymphoma) ¶ ¶ À + À GACTCCATTCCCAAC-3 and 5 -CAAGAGAATTCGTTCAGTCTGAAT- and the CD30 /CD153 cell line DG75 (Burkitt lymphoma) and the CD30 / ¶ À TACTGTATAAGAAGATGGAC-3 .AfterBamHI and EcoRI restriction CD153 cell line Reh (acute lymphoblastic leukemia). In addition, we used the digest, the PCR product was cloned into the glutathione S-transferase mast cell line HMC-1, which was kindly provided by Dr. J. Butterfield (Mayo (GST) expression vector (pGEX-3X, Amersham Pharmacia Biotech, Clinic, Rochester, MN); the ADAM17-targeted mouse fibroblast cells, which Freiburg, Germany). BL21 cells (DE3) were transformed and induced for were received from Dr. R. Black (Amgen Incorporated, Seattle, WA); and 5 hby isopropyl- L-thio-h-D-galactopyranoside (0.5 mmol/L). The bacterial À/À the ADAM10 ( ) cells, which were a gift of Dr. D. Hartmann (Center for pellet was suspended in 20 mmol/L Tris-HCl (pH 8) containing 150 Human Genetics, Leuven, Belgium). The hydroxamate inhibitor BB-3644 mmol/L NaCl, 1 mmol/L EDTA, 5 mmol/L h-mercaptoethanol, 1% Triton 1 [2S-(2,2-dimethyl-propyl)-N -[2,2-dimethyl-1-(pyridin-2S-ylcarbamoyl)- X-100, and complete protease inhibitor cocktail (Roche Diagnostics, 4 propyl]-N -hydroxy-3R-methoxy-succinamide] was from British Biotech Mannheim, Germany). Lysozyme (0.5 mg/mL) was added to the Pharmaceuticals Ltd. (Oxford, United Kingdom). GW280264 [(2R,3S)-3- suspension before sonication on ice (3Â, 15 s). After centrifugation for (formylhydroxyamino)-2-(2-methyl-1-propyl) hexanoic acid (1S)-5-(benzy- 40 min at 35,000 Â g and 4jC, the recombinant protein was extracted loxycarbamoyl-amino-1-(1,3-thiazol-2-ylcarbamoyl)-1-pentyl amide)] and from the cell lysate by incubation with glutathione-conjugated agarose GI254023X [(2R,3S)-3-( formyl-hydroxyamino)-2-(3-phenyl-1-propyl) buta- beads (GSH-agarose; Amersham Pharmacia Biotech). The beads were noic acid [(1S)-2,2-dimetyl-1-methylcarbamoyl-1-propyl] amide] were from washed with lysis buffer without Triton X-100 and stored in 50 mmol/L GlaxoSmithKline (Stevenage, United Kingdom). Recombinant ADAM10 was Tris-HCl (pH 8). from Merck Biosciences (Schwalbach, Germany), and ADAM17 was from Transfection. Cells were transfected as described previously (17). R&D Systems (Wiesbaden, Germany). Transfection with cDNA for enhanced green fluorescence protein (Clontech, Plasmids. Construction of recombinant CD30Fc. The CD30Fc fusion Palo Alto, CA) was used to monitor the transfection efficiency. protein containing the Fc portion of human IgG1 and the truncated Production and purification of sCD30. 293T cells were transfected ectodomain of human CD30 (deletion between 89Arg and 156Arg) was withCD30Fc or wild-type CD30 cDNA. After 48 hof incubation, CD30Fc or constructed by PCR using the CD30 cDNA clone (17), the HindIII forward sCD30 was purified from the supernatants using Protein A Sepharose CL-4B primer 5¶-GCGAGAAGCTTATGCGCGTCCTCCTCGCCGCG-3¶,andthe beads (Amersham Pharmacia Biotech)
Load more

Recommended publications
  • Neprilysin Is Required for Angiotensin-(1-7)
    Page 1 of 39 Diabetes NEPRILYSIN IS REQUIRED FOR ANGIOTENSIN-(1-7)’S ABILITY TO ENHANCE INSULIN SECRETION VIA ITS PROTEOLYTIC ACTIVITY TO GENERATE ANGIOTENSIN-(1-2) Gurkirat S. Brara, Breanne M. Barrowa, Matthew Watsonb, Ryan Griesbachc, Edwina Chounga, Andrew Welchc, Bela Ruzsicskad, Daniel P. Raleighb, Sakeneh Zraikaa,c aVeterans Affairs Puget Sound Health Care System, Seattle, WA 98108, United States bDepartment of Chemistry, Stony Brook University, Stony Brook, NY 11794, United States cDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98195, United States dInstitute for Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794, United States Short Title: Angiotensin-(1-7) and insulin secretion Word count: 3997; Figure count: 8 main (plus 3 Online Suppl.); Table count: 1 Online Suppl. Correspondence to: Sakeneh Zraika, PhD 1660 South Columbian Way (151) Seattle, WA, United States Tel: 206-768-5391 / Fax: 206-764-2164 Email: [email protected] 1 Diabetes Publish Ahead of Print, published online May 30, 2017 Diabetes Page 2 of 39 ABSTRACT Recent work has renewed interest in therapies targeting the renin-angiotensin system (RAS) to improve β-cell function in type 2 diabetes. Studies show that generation of angiotensin-(1-7) by angiotensin converting enzyme 2 (ACE2) and its binding to the Mas receptor (MasR) improves glucose homeostasis, partly by enhancing glucose-stimulated insulin secretion (GSIS). Thus, islet ACE2 upregulation is viewed as a desirable therapeutic goal. Here, we show that although endogenous islet ACE2 expression is sparse, its inhibition abrogates angiotensin-(1-7)-mediated GSIS. However, a more widely expressed islet peptidase, neprilysin, degrades angiotensin-(1-7) into several peptides.
    [Show full text]
  • 3 Cleavage Products of Notch 2/Site and Myelopoiesis by Dysregulating
    ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch This information is current as David R. Gibb, Sheinei J. Saleem, Dae-Joong Kang, Mark of October 4, 2021. A. Subler and Daniel H. Conrad J Immunol 2011; 186:4244-4252; Prepublished online 2 March 2011; doi: 10.4049/jimmunol.1003318 http://www.jimmunol.org/content/186/7/4244 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2011/03/02/jimmunol.100331 Material 8.DC1 http://www.jimmunol.org/ References This article cites 45 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/186/7/4244.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 4, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch David R.
    [Show full text]
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
    [Show full text]
  • Cell-Autonomous FLT3L Shedding Via ADAM10 Mediates Conventional Dendritic Cell Development in Mouse Spleen
    Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen Kohei Fujitaa,b,1, Svetoslav Chakarovc,1, Tetsuro Kobayashid, Keiko Sakamotod, Benjamin Voisind, Kaibo Duanc, Taneaki Nakagawaa, Keisuke Horiuchie, Masayuki Amagaib, Florent Ginhouxc, and Keisuke Nagaod,2 aDepartment of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan; bDepartment of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan; cSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, 138648 Singapore; dDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892; and eDepartment of Orthopedic Surgery, National Defense Medical College, Tokorozawa 359-8513, Japan Edited by Kenneth M. Murphy, Washington University School of Medicine, St. Louis, MO, and approved June 10, 2019 (received for review November 4, 2018) Conventional dendritic cells (cDCs) derive from bone marrow (BM) intocDC1sorcDC2stakesplaceintheBM(3),andthese precursors that undergo cascades of developmental programs to pre-cDC1s and pre-cDC2s ultimately differentiate into cDC1s terminally differentiate in peripheral tissues. Pre-cDC1s and pre- and cDC2s after migrating to nonlymphoid and lymphoid tissues. + + cDC2s commit in the BM to each differentiate into CD8α /CD103 cDCs are short-lived, and their homeostatic maintenance relies + cDC1s and CD11b cDC2s, respectively. Although both cDCs rely on on constant replenishment from the BM precursors (5). The cy- the cytokine FLT3L during development, mechanisms that ensure tokine Fms-related tyrosine kinase 3 ligand (FLT3L) (12), by cDC accessibility to FLT3L have yet to be elucidated. Here, we gen- signaling through its receptor FLT3 expressed on DC precursors, erated mice that lacked a disintegrin and metalloproteinase (ADAM) is essential during the development of DCs (7, 13).
    [Show full text]
  • Gene Pval Qval Log2 Fold Change AAMP 0.895690332 0.952598834
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut Gene pval qval Log2 Fold Change AAMP 0.895690332 0.952598834 -0.21 ABI3BP 0.002302151 0.020612283 0.465 ACHE 0.103542461 0.296385483 -0.16 ACTG2 2.99E-07 7.68E-05 3.195 ACVR1 0.071431098 0.224504378 0.19 ACVR1C 0.978209579 0.995008423 0.14 ACVRL1 0.006747504 0.042938663 0.235 ADAM15 0.158715519 0.380719469 0.285 ADAM17 0.978208929 0.995008423 -0.05 ADAM28 0.038932876 0.152174187 -0.62 ADAM8 0.622964796 0.790251882 0.085 ADAM9 0.122003358 0.329623107 0.25 ADAMTS1 0.180766659 0.414256926 0.23 ADAMTS12 0.009902195 0.05703885 0.425 ADAMTS8 4.60E-05 0.001169089 1.61 ADAP1 0.269811968 0.519388039 0.075 ADD1 0.233702809 0.487695826 0.11 ADM2 0.012213453 0.066227879 -0.36 ADRA2B 0.822777921 0.915518785 0.16 AEBP1 0.010738542 0.06035531 0.465 AGGF1 0.117946691 0.320915024 -0.095 AGR2 0.529860903 0.736120272 0.08 AGRN 0.85693743 0.928047568 -0.16 AGT 0.006849995 0.043233572 1.02 AHNAK 0.006519543 0.042542779 0.605 AKAP12 0.001747074 0.016405449 0.51 AKAP2 0.409929603 0.665919397 0.05 AKT1 0.95208288 0.985354963 -0.085 AKT2 0.367391504 0.620376005 0.055 AKT3 0.253556844 0.501934205 0.07 ALB 0.064833867 0.21195036 -0.315 ALDOA 0.83128831 0.918352939 0.08 ALOX5 0.029954404 0.125352668 -0.3 AMH 0.784746815 0.895196237 -0.03 ANG 0.050500474 0.181732067 0.255 ANGPT1 0.281853305 0.538528647 0.285 ANGPT2 0.43147281 0.675272487 -0.15 ANGPTL2 0.001368876 0.013688762 0.71 ANGPTL4 0.686032669 0.831882134 -0.175 ANPEP 0.019103243 0.089148466 -0.57 ANXA2P2 0.412553021 0.665966092 0.11 AP1M2 0.87843088 0.944681253 -0.045 APC 0.267444505 0.516134751 0.09 APOD 1.04E-05 0.000587404 0.985 APOE 0.023722987 0.104981036 -0.395 APOH 0.336334555 0.602273505 -0.065 Sundar R, et al.
    [Show full text]
  • Gene Standard Deviation MTOR 0.12553731 PRPF38A
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut Gene Standard Deviation MTOR 0.12553731 PRPF38A 0.141472605 EIF2B4 0.154700091 DDX50 0.156333027 SMC3 0.161420017 NFAT5 0.166316903 MAP2K1 0.166585267 KDM1A 0.16904912 RPS6KB1 0.170330192 FCF1 0.170391706 MAP3K7 0.170660513 EIF4E2 0.171572093 TCEB1 0.175363093 CNOT10 0.178975095 SMAD1 0.179164705 NAA15 0.179904998 SETD2 0.180182498 HDAC3 0.183971158 AMMECR1L 0.184195031 CHD4 0.186678211 SF3A3 0.186697697 CNOT4 0.189434633 MTMR14 0.189734199 SMAD4 0.192451524 TLK2 0.192702667 DLG1 0.19336621 COG7 0.193422331 SP1 0.194364189 PPP3R1 0.196430217 ERBB2IP 0.201473001 RAF1 0.206887192 CUL1 0.207514271 VEZF1 0.207579584 SMAD3 0.208159809 TFDP1 0.208834504 VAV2 0.210269344 ADAM17 0.210687138 SMURF2 0.211437666 MRPS5 0.212428684 TMUB2 0.212560675 SRPK2 0.216217428 MAP2K4 0.216345366 VHL 0.219735582 SMURF1 0.221242495 PLCG1 0.221688351 EP300 0.221792349 Sundar R, et al. Gut 2020;0:1–10. doi: 10.1136/gutjnl-2020-320805 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut MGAT5 0.222050228 CDC42 0.2230598 DICER1 0.225358787 RBX1 0.228272533 ZFYVE16 0.22831803 PTEN 0.228595789 PDCD10 0.228799406 NF2 0.23091035 TP53 0.232683696 RB1 0.232729172 TCF20 0.2346075 PPP2CB 0.235117302 AGK 0.235416298
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
    HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
    [Show full text]
  • Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19
    https://www.scientificarchives.com/journal/journal-of-cellular-signaling Journal of Cellular Signaling Commentary Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19 Rui Yamaguchi, Yasuo Yamaguchi* Graduate School of Medical Science, Kumamoto Health Science University, Kitaku Izumi-machi 325 Kumamoto 861-5598, Japan *Correspondence should be addressed to Yasuo Yamaguchi; [email protected] Received date: April 16, 2021, Accepted date: May 21, 2021 Copyright: © 2021 Yamaguchi R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Ectodomain shedding mediated by a disintegrin and (ROS) [2]. ADAM10/7 was found to mediate ectodomain metalloprotease 10/17 (ADAM10/17) modulates the shedding to modulate immune responses [3] and to function of immune effector cells and may be involved in be activated by ROS [4]. These findings suggest that the novel coronavirus disease COVID-19. Toll-like receptor SARS-CoV-2 contributes to and induces ectodomain 7/8 (TLR7/8) recognizes single-strand RNA from viruses shedding, which may be associated with disease severity. such as severe acute respiratory syndrome coronavirus In patients with COVID-19, studies found a higher blood 2 (SARS-CoV-2, the virus that causes COVID-19) during concentration of the chemokine fractalkine [5]. Cell the innate immune response [1], and TLR7/8 agonist membrane-bound angiotensin-converting enzyme 2 activates nicotinamide adenine dinucleotide phosphate (ACE2) has been identified as a binding site and entry (NADPH) oxidase to generate reactive oxygen species receptor for the spike protein of SARS-CoV-2.
    [Show full text]
  • The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex
    The Journal of Neuroscience, April 7, 2010 • 30(14):4833–4844 • 4833 Development/Plasticity/Repair The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex Ellen Jorissen,1,2* Johannes Prox,3* Christian Bernreuther,4 Silvio Weber,3 Ralf Schwanbeck,3 Lutgarde Serneels,1,2 An Snellinx,1,2 Katleen Craessaerts,1,2 Amantha Thathiah,1,2 Ina Tesseur,1,2 Udo Bartsch,5 Gisela Weskamp,6 Carl P. Blobel,6 Markus Glatzel,4 Bart De Strooper,1,2 and Paul Saftig3 1Center for Human Genetics, Katholieke Universiteit Leuven and 2Department for Developmental and Molecular Genetics, Vlaams Instituut voor Biotechnologie (VIB), 3000 Leuven, Belgium, 3Institut fu¨r Biochemie, Christian-Albrechts-Universita¨t zu Kiel, D-24098 Kiel, Germany, 4Institute of Neuropathology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, 5Department of Ophthalmology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, and 6Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, and Departments of Medicine and of Physiology, Systems Biology and Biophysics, Weill Medical College of Cornell University, New York, New York 10021 The metalloproteinase and major amyloid precursor protein (APP) ␣-secretase candidate ADAM10 is responsible for the shedding of ,proteins important for brain development, such as cadherins, ephrins, and Notch receptors. Adam10 ؊/؊ mice die at embryonic day 9.5 due to major defects in development of somites and vasculogenesis. To investigate the function of ADAM10 in brain, we generated Adam10conditionalknock-out(cKO)miceusingaNestin-Crepromotor,limitingADAM10inactivationtoneuralprogenitorcells(NPCs) and NPC-derived neurons and glial cells. The cKO mice die perinatally with a disrupted neocortex and a severely reduced ganglionic eminence, due to precocious neuronal differentiation resulting in an early depletion of progenitor cells.
    [Show full text]
  • ADAM10 Controls Collagen Signaling and Cell Migration on Collagen by Shedding the Ectodomain of Discoidin Domain Receptor 1 (DDR1)
    M BoC | ARTICLE ADAM10 controls collagen signaling and cell migration on collagen by shedding the ectodomain of discoidin domain receptor 1 (DDR1) Yasuyuki Shitomia, Ida B. Thøgersenb, Noriko Itoa, Birgit Leitingerc, Jan J. Enghildb, and Yoshifumi Itoha aKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7FY, United Kingdom; bDepartment of Molecular Biology and Genetics, University of Aarhus, DK-8000 Aarhus C, Denmark; cNational Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom ABSTRACT Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that binds and Monitoring Editor transmits signals from various collagens in epithelial cells. However, how DDR1–dependent Jean E. Schwarzbauer signaling is regulated has not been understood. Here we report that collagen binding in- Princeton University duces ADAM10-dependent ectodomain shedding of DDR1. DDR1 shedding is not a result of Received: Oct 21, 2014 an activation of its signaling pathway, since DDR1 mutants defective in signaling were shed Revised: Dec 4, 2014 in an efficient manner. DDR1 and ADAM10 were found to be in a complex on the cell surface, Accepted: Dec 16, 2014 but shedding did not occur unless collagen bound to DDR1. Using a shedding-resistant DDR1 mutant, we found that ADAM10-dependent DDR1 shedding regulates the half-life of colla- gen-induced phosphorylation of the receptor. Our data also revealed that ADAM10 plays an important role in regulating DDR1-mediated cell adhesion to achieve efficient cell migration on collagen matrices. INTRODUCTION Extracellular matrix (ECM) is essential in multicellular organisms to discoidin domain receptors (DDRs), glycoprotein VI, leukocyte-asso- maintain functional tissue structures; it acts as scaffolding to support ciated, immunoglobulin-like receptors, and mannose receptors such cell migration and as a reservoir for growth factors.
    [Show full text]
  • Cleavage of the Extracellular Domain of Junctional Adhesion Molecule-A Is Associated with Resistance to Anti-HER2 Therapies in Breast Cancer Settings Astrid O
    Leech et al. Breast Cancer Research (2018) 20:140 https://doi.org/10.1186/s13058-018-1064-1 RESEARCH ARTICLE Open Access Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings Astrid O. Leech1, Sri HariKrishna Vellanki1†, Emily J. Rutherford1†, Aoife Keogh1, Hanne Jahns2, Lance Hudson1, Norma O’Donovan3, Siham Sabri4, Bassam Abdulkarim5, Katherine M. Sheehan6, Elaine W. Kay6, Leonie S. Young1, Arnold D. K. Hill1, Yvonne E. Smith1 and Ann M. Hopkins1* Abstract Background: Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive disease. Since JAM-A has been described to regulate HER2 expression in breast cancer cells, we hypothesized that JAM-dependent stabilization of HER2 could participate in resistance to HER2-targeted therapies. Methods: Using breast cancer cell line models resistant to anti-HER2 drugs, we investigated JAM-A expression and the effect of JAM-A silencing on biochemical/functional parameters. We also tested whether altered JAM-A expression/ processing underpinned differences between drug-sensitive and -resistant cells and acted as a biomarker of patients who developed resistance to HER2-targeted therapies. Results: Silencing JAM-A enhanced the anti-proliferative effects of anti-HER2 treatments in trastuzumab- and lapatinib- resistant breast cancer cells and further reduced HER2 protein expression and Akt phosphorylation in drug-treated cells. Increased epidermal growth factor receptor expression observed in drug-resistant models was normalized upon JAM-A silencing.
    [Show full text]